which is estimated at more than 15%. 4,5 Fortunately most APE patients are hemodynamically stable at admission but the early mortality risk is different in this population. Risk stratification of non-high-risk APE patients is based on clinical presentation, cardiac laboratory biomarkers, and signs of right ventricular (RV) dysfunction on echocardiography or computed tomography. 4,6 Low-risk patients require a short hospital stay and can be early discharged home or even treated as outpatients. 7 Intermediate-risk subjects comprise a very heterogeneous group in which the early mortality ranges between 2% and 15%. 4 More of A cute pulmonary embolism (APE) is the most serious clinical presentation of venous thromboembolism (VTE). According to registries and hospital discharge databases of unselected patients with APE and VTE, 30-day all-cause mortality rates are between 9% and 10%. 1-3 According to the recent European Society of Cardiology (ESC) guidelines on the diagnosis and treatment of APE patients, clinical classification of the severity of an episode of APE is based on the estimated 30-day APErelated mortality risk. 4 Patients with cardiogenic shock caused by APE comprise a high-risk group for early death, Background: Patients with intermediate-risk acute pulmonary embolism (APE) are a heterogeneous group with an early mortality rate of 2-15%. The tricuspid annulus plane systolic excursion (TAPSE) and tricuspid regurgitation peak gradient (TRPG) can be used for risk stratification, so we analyzed the prognostic value of a new echo parameter (TRPG/TAPSE) for prediction of APE-related 30-day death or need for rescue thrombolysis in initially normotensive APE patients.